[et_pb_section fb_built=”1″ admin_label=”Listings” module_id=”target group” _builder_version=”4.27.5″ _module_preset=”default” background_color=”#FFFFFF” background_enable_image=”off” background_size=”custom” background_image_width=”90%” background_position=”bottom_right” top_divider_height=”51px” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row use_custom_gutter=”on” gutter_width=”3″ _builder_version=”4.27.5″ _module_preset=”default” width=”100%” custom_margin=”|auto|-1px|auto|false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” _builder_version=”4.27.5″ _module_preset=”default” title_text_color=”#10344C” title_font_size=”45px” custom_margin=”||15px|||” global_colors_info=”{}”][\/et_pb_post_title][et_pb_text _builder_version=”4.27.5″ _module_preset=”1f09816e-184e-4ce5-a4cf-b39c52c423ca” text_font=”–et_global_body_font||||||||” text_text_color=”#10344C” text_font_size=”20px” text_line_height=”1.8em” ul_line_height=”1.8em” custom_margin=”||||false|false” hover_enabled=”0″ text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”55px” header_font_size_last_edited=”off|desktop” global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
ClinicalTrials.gov ID:<\/strong> NCT05242484 Official title:<\/strong> Study overview:<\/strong> [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" ClinicalTrials.gov ID: NCT05242484Sponsor: Janssen Research & Development, LLC Official title:A Phase 2b Randomized, Double-Blind, Active and Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of Guselkumab and Golimumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis. Study overview:Study to Evaluate the Efficacy and Safety of JNJ-78934804 Compared to […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[37,36],"tags":[],"class_list":["post-398","post","type-post","status-publish","format-standard","hentry","category-active-recruitment-completed","category-for-study-partners"],"yoast_head":"\n
Sponsor:<\/strong> Janssen Research & Development, LLC<\/p>\n
A Phase 2b Randomized, Double-Blind, Active and Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of Guselkumab and Golimumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.<\/p>\n
Study to Evaluate the Efficacy and Safety of JNJ-78934804 Compared to Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis Who Have Had an Inadequate Response, Loss of Response, or Intolerance to at Least One Approved Advanced Therapy.<\/p>\n